Here, we delineate a unique molecular mechanism by which GR is activated by cisplatin and steroid, and how the activation of GR contributes to platinum resistance in human cancers through MAST1 using a series of preclinical studies and analysis of platinum-treated patient tumor specimens. This evidence concerns the gene NR3C1 and cancer.